Recent studies have focused on the intersection of glucagon-like peptide-1|GIP|GCGR agonist therapies and DA neurotransmission. While GIP stimulators are widely employed for managing type 2 T2DM, their potential effects on motivation circuits, specifically mediated by dopaminergic systems, are gaining significant focus. This article provides a conc